Seqera Labs, a provider of data organization and workflow software for the life sciences sector, has raised €22 million in a capital increase.
According to a statement, the financing has been provided mainly by the US investment fund Addition and has had the support of Talis Capital, Speedinvest, BoxOne Ventures and Amino Collective.
Seqera Labs was created in 2018 as an emerging company -or spin-off- of the Center for Genomic Regulation. The company's purpose was to develop the technology behind the Nextflow platform, which offers open source workflow and data organization for the healthcare industry. The founders of both businesses are Evan Floden and Paolo Di Tommaso.
In the past, Seqera Labs had raised another €4 million. Now investors trust in the potential of technology again. According to the statement, the software allows (among other applications) to detect and track the different variants of covid. Among its services, the 'Tower' platform stands out, which has been adopted by more than 150 pharmaceutical and biotech companies, including AstraZeneca, Janssen Pharmaceuticals and Oxford Nanopore.
Parallel to this latest round of financing, Seqera Labs and the Center for Genomic Regulation (which depends on the Generalitat) have signed an agreement on intellectual property whereby the start-up takes control of the assets related to the Nextflow technology.
